Beta Drugs Ltd. (BDL) received registration certificates for 20 injectables from Ministry of Health Uzbekistan, for their Indian manufacturing facility for the injectable line for both lyophilized and liquids (Carboplatin 150 & 450mg, Docetaxel 20, 80 & 100mg, Doxorubicin 50 & 100mg, Gemcitabine 200 & 1000mg, Paclitaxel 30, 100 & 260mg, Cisplatin 10 & 50mg, Oxaliplatin 50 & 100mg, Bortezomib 2mg, Pemetrexed 100 & 500mg injections, NAB Paclitaxel 100mg injections). Beta will become the first company to market highly technology intensive product NAB Paclitaxel 100mg in Uzbekistan. This will help the company to establish itself as a technology driven company focused on offering technically superior products. With the Uzbekistan JV & receipt of 20 registration certificates, BDL will be able to manufacture locally & export oncology injectables to Uzbekistan from its Indian plant. It has started building its marketing & sales operations in Uzbekistan covering all oncology hospitals. In addition, BDL being the oncology manufacturing company is now eligible to participate in local and national tenders in Uzbekistan for the products it received registrations and will also get preference in award of tenders for the products manufactured by the company in its Bekabad plant in Uzbekistan.